<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOXERCALCIFEROL</span><br/>(dox-er-kal'si-fe-rol)<br/><span class="topboxtradename">Hectorol<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">vitamin d analog</span><br/><b>Prototype: </b>Calcitriol<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mcg, 2.5 mcg capsule; 2 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Vitamin D<sub>2</sub> analog that is activated by the liver. Regulates the blood calcium levels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Activated Vitamin D is needed for absorption of dietary calcium in the intestine, and the parathyroid hormone (PTH) which
         mobilizes calcium from the bone tissue.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of elevated iPTH in secondary hyperparathyroidism in patients undergoing chronic renal dialysis; secondary hyperparathyroidism
         in chronic kidney disease not on dialysis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to doxercalciferol or other Vitamin D analogs; recent hypercalcemia, recent hyperphosphatemia, hypervitaminosis
         D; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic insufficiency; renal osteodystrophy with hyperphosphatemia, prolonged hypercalcemia; pregnancy (category
         B). Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Secondary Hyperparathyroidism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mcg 3 times per wk at dialysis, adjust dose as needed to lower iPTH into the range of 150300 pg/mL by increasing
               the dose in 2.5 mcg  increments every 8 wks (max: 60 mcg/wk) <span class="rdroute">IV</span> 4 mcg 3 times/wk at end of dialysis (max: 18 mcg/wk)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at time of dialysis.</li>
<li>Withhold drug and notify physician if any of the following occurs: iPTH 70.
         </li>
<li>Use beyond 16 wk is not recommended.</li>
<li>Store at 20°25° C (66°77° F); excursions to 15°30° C (59°86°
            F) are permitted.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span>  No dilution is needed. Withdraw appropriate dose from ampule using a filter needle. Change needles before injecting as an IV bolus. Discard any unused portion. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a bolus injection at the end of dialysis sessions.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°20° C (59°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Abscess, <span class="speceff-common">headache, malaise,</span> arthralgia. <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness,</span> sleep disorder. <span class="typehead">CV:</span> Bradycardia, <span class="speceff-common">edema</span>. <span class="typehead">GI:</span> Anorexia, constipation, dyspepsia, <span class="speceff-common">nausea, vomiting</span>. <span class="typehead">Respiratory:</span> <span class="speceff-common">Dyspnea</span>. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Other:</span> Weight gain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Cholestyramine,</b> <b>mineral oil</b> may decrease absorption; <span class="classification">magnesium-containing antacids</span> may cause hypermagnesemia; other <span class="classification">vit d analogs</span> may increase toxicity and hypercalcemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorbed from GI tract and is activated in the liver. <span class="typehead">Peak:</span> 1112 h. <span class="typehead">Metabolism:</span> Activated by CYP 27 to form 1alpha, 25-(OH)<sub>2</sub>D<sub>2</sub> (major metabolite) and 1alpha, 24-dihydroxyvitamin D<sub>2</sub> (minor metabolite). <span class="typehead">Half-Life:</span> 3237 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic iPTH, serum calcium, serum phosphorus. Monitor levels weekly during dose titration.</li>
<li>Monitor for S&amp;S of hypercalcemia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take antacids without consulting the physician.</li>
<li>Notify the physician if you become pregnant while taking this drug.</li>
<li>Do not use mineral oil on the days doxercalciferol is taken. Mineral oil may decrease absorption of drug.</li>
<li>Do not take nonprescription drugs containing magnesium while taking doxercalciferol.</li>
<li>Report S&amp;S of hypercalcemia immediately: Bone or muscle pain, dry mouth with metallic taste, rhinorrhea, itching, photophobia,
            conjunctivitis, frequent urination, anorexia and weight loss.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>